Why the study?
Venous thromboembolism is a major cause of maternal morbidity, but adequate study data are lacking, requiring evidence synthesis to establish a more uniform strategy for risk assessment and thromboprophylaxis.
This position paper provides expert consensus on VTE risk assessment and thromboprophylaxis strategies for pregnant and postpartum women, particularly those with hereditary thrombophilia or prior VTE.
Supports individualized VTE prophylaxis decisions in pregnancy; extends Level 1 consensus on risk-benefit stratification.
Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. Because there is a lack of adequate study data, management strategies for the prevention of VTE during pregnancy have mainly been deduced from case-control and observational studies and extrapolated from recommendations for non-pregnant patients. The decision for or against pharmacologic thromboprophylaxis must be made on an individual basis weighing the risk of VTE against the risk of adverse side effects such as severe bleeding complications. A comprehensive, multidisciplinary approach is often essential as the clinical scenario is made more complex by the specific obstetric context, especially in the peripartum period. As members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH), we summarize the evidence from the available literature and aim to establish a more uniform strategy for VTE risk assessment and thromboprophylaxis in pregnancy and the puerperium. In this document, we focus on women with hereditary thrombophilia, prior VTE and the use of anticoagulants that can safely be applied during pregnancy and the lactation period.
No takes yet. Share an insight, caveat, or question.
Hart et al. (2020) conducted a review in Venous thromboembolism (VTE) during pregnancy and the puerperium. Pharmacologic thromboprophylaxis (anticoagulants) was evaluated. Pharmacologic thromboprophylaxis in pregnant women with hereditary thrombophilia or prior VTE requires an individualized approach weighing VTE risk against bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: